Bradley & Co Private Wealth Management’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$19.6K Hold
100
0.01% 116
2025
Q4
$17.4K Hold
100
0.01% 118
2025
Q3
$19.1K Hold
100
0.01% 111
2025
Q2
$18K Hold
100
0.01% 107
2025
Q1
$16.9K Hold
100
0.01% 109
2024
Q4
$15.1K Buy
+100
New +$15.6K 0.01% 110
2024
Q2
$13.7K Hold
100
0.01% 108
2024
Q1
$13.3K Hold
100
0.01% 112
2023
Q4
$13.8K Hold
100
0.01% 112
2023
Q3
$12.2K Hold
100
0.01% 108
2023
Q2
$14.1K Hold
100
0.01% 108
2023
Q1
$14.1K Hold
100
0.02% 109
2022
Q4
$15.6K Hold
100
0.02% 106
2022
Q3
$12K Hold
100
0.01% 120
2022
Q2
$13K Hold
100
0.01% 128
2022
Q1
$14K Hold
100
0.01% 121
2021
Q4
$17K Hold
100
0.01% 124
2021
Q3
$15K Hold
100
0.01% 129
2021
Q2
$13K Hold
100
0.01% 132
2021
Q1
$13K Buy
+100
New +$12.3K 0.01% 134

Other funds holding DGX

Bradley & Co Private Wealth Management's DGX Position: Q1 2026 in Review

Bradley & Co Private Wealth Management held its Quest Diagnostics (DGX) position steady in Q1 2026 at 100 shares worth $19.6K. The position accounts for 0.01% of the portfolio, ranked #116.

Bradley & Co Private Wealth Management first reported a position in DGX in Q1 2021 and has held it in 20 quarters since. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Bradley & Co Private Wealth Management held 100 shares of Quest Diagnostics worth $19.6K as of Q1 2026.
  • Bradley & Co Private Wealth Management left its Quest Diagnostics share count unchanged in Q1 2026.
  • Quest Diagnostics made up 0.01% of Bradley & Co Private Wealth Management's portfolio in Q1 2026, its #116 holding.
  • Bradley & Co Private Wealth Management first reported a position in Quest Diagnostics in Q1 2021 and has held it in 20 quarters since.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Bradley & Co Private Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.